Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Trial Profile

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2018 Results from ACP-103-020 and ACP-103-012 studies published in the Clinical Neuropharmacology.
    • 18 Jun 2015 Pooled analysis (ACP103-020 and ACP103-012) Efficacy and tolerability results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 16 Jun 2015 According to an Acadia Pharmaceuticals media release, data from this study were presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top